[go: up one dir, main page]

CA2142861A1 - Usages nouveaux de l'interleukine 4 et/ou de l'interleukine 10, et anticorps diriges contre celles-ci - Google Patents

Usages nouveaux de l'interleukine 4 et/ou de l'interleukine 10, et anticorps diriges contre celles-ci

Info

Publication number
CA2142861A1
CA2142861A1 CA 2142861 CA2142861A CA2142861A1 CA 2142861 A1 CA2142861 A1 CA 2142861A1 CA 2142861 CA2142861 CA 2142861 CA 2142861 A CA2142861 A CA 2142861A CA 2142861 A1 CA2142861 A1 CA 2142861A1
Authority
CA
Canada
Prior art keywords
antibodies against
combination
another embodiment
still another
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2142861
Other languages
English (en)
Other versions
CA2142861C (fr
Inventor
Robert Coffman
Jan E. De Vries
Rene De Waal Malefyt
Fiona Powrie
Donna Rennick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Individual filed Critical Individual
Publication of CA2142861A1 publication Critical patent/CA2142861A1/fr
Application granted granted Critical
Publication of CA2142861C publication Critical patent/CA2142861C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
CA002142861A 1992-08-20 1993-08-18 Usages nouveaux de l'interleukine 4 et/ou de l'interleukine 10, et anticorps diriges contre celles-ci Expired - Fee Related CA2142861C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US07/932,900 1992-08-20
US93341992A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
US07/933,462 1992-08-21
US07/933,950 1992-08-21
US07/933,419 1992-08-21
PCT/US1993/007646 WO1994004180A2 (fr) 1992-08-20 1993-08-18 Nouvelles utilisations d'il-4 et/ou d'il-10, et anticorps diriges contre ces dernieres

Publications (2)

Publication Number Publication Date
CA2142861A1 true CA2142861A1 (fr) 1994-03-03
CA2142861C CA2142861C (fr) 2000-08-15

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142861A Expired - Fee Related CA2142861C (fr) 1992-08-20 1993-08-18 Usages nouveaux de l'interleukine 4 et/ou de l'interleukine 10, et anticorps diriges contre celles-ci

Country Status (23)

Country Link
EP (2) EP0801951A3 (fr)
JP (1) JP3494647B2 (fr)
KR (1) KR0170037B1 (fr)
CN (1) CN1090204A (fr)
AT (1) ATE162947T1 (fr)
AU (1) AU680628B2 (fr)
CA (1) CA2142861C (fr)
CZ (1) CZ283488B6 (fr)
DE (1) DE69316921T2 (fr)
DK (1) DK0671933T3 (fr)
ES (1) ES2111769T3 (fr)
FI (1) FI950697L (fr)
GR (1) GR3026635T3 (fr)
HK (1) HK1004326A1 (fr)
HU (1) HU220103B (fr)
IL (1) IL106725A (fr)
MX (1) MX9305054A (fr)
MY (1) MY111402A (fr)
PL (1) PL307566A1 (fr)
RU (1) RU2120802C1 (fr)
SK (1) SK21195A3 (fr)
TW (1) TW243415B (fr)
WO (1) WO1994004180A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0681589A1 (fr) * 1993-02-01 1995-11-15 Université Libre de Bruxelles Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
BR9508243A (pt) 1994-07-05 1997-10-21 Steeno Res Group As Imunomoduladores
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
CA2205572A1 (fr) 1994-12-12 1996-06-20 Beth Israel Hospital Association Cytokines chimeres et emplois de celles-ci
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (fr) * 1995-08-01 1997-02-05 Institut Pasteur Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
JP2000508654A (ja) * 1996-04-17 2000-07-11 プレンデルガスト，パトリック，ティー Ｄｈｅａ組合せ療法
WO1998027997A1 (fr) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. Methode diagnostique et therapeutique contre les maladies intestinales inflammatoires, notamment la maladie de crohn et la colite ulcereuse chronique
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
IL144826A0 (en) 1999-02-10 2002-06-30 Welfide Corp Amide compounds and pharmaceutical compositions containing the same
EP2295968B1 (fr) * 1999-12-03 2012-09-19 Baxter International Inc. Essai de pyrogenicité à utiliser avec des systèmes de dosage immunologique automatisés
CA2404365A1 (fr) * 2000-03-31 2001-10-11 Idec Pharmaceutical Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
WO2001087330A2 (fr) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
ES2607988T3 (es) 2005-05-31 2017-04-05 Iams Europe B.V. Bifidobacterias probióticas felinas
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
EP1931762B1 (fr) * 2005-10-03 2012-12-05 Actogenix N.V. Utilisation d'une souche de levure recombinante produisant un compose anti-inflammatoire pour la fabrication d'un medicament destine au traitement de la colite
EP2821078B1 (fr) * 2006-09-28 2016-09-21 Merck Sharp & Dohme Corp. Il-10 pegylée pour son utilisation dans le traitement de lymphomes
BRPI0808391A2 (pt) 2007-02-01 2014-07-08 Lams Company Método para diminuir a inflamação e o estresse em um mamífero, mediante o uso de antimetabólitos de glicose, abacate ou extratos de abacate.
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CA2908198A1 (fr) * 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2014204816A2 (fr) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Méthode d'évaluation de l'identité et de la stabilité d'une protéine
SMT201800655T1 (it) 2013-07-18 2019-01-11 Univ Colorado Regents Composizione per il trattamento di una malattia infiammatoria articolare
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DK0567576T3 (da) * 1991-01-16 1995-06-12 Schering Corp Behandling af neoplastiske sygdomme med interleukin-10
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
HUT70976A (en) 1995-11-28
SK21195A3 (en) 1996-10-02
CZ44195A3 (en) 1995-10-18
DE69316921D1 (de) 1998-03-12
WO1994004180A3 (fr) 1994-06-09
HU9500467D0 (en) 1995-04-28
EP0671933A1 (fr) 1995-09-20
IL106725A0 (en) 1993-12-08
HK1004326A1 (en) 1998-11-20
DE69316921T2 (de) 1998-06-04
GR3026635T3 (en) 1998-07-31
KR950702841A (ko) 1995-08-23
WO1994004180A2 (fr) 1994-03-03
TW243415B (fr) 1995-03-21
MX9305054A (es) 1994-02-28
AU680628B2 (en) 1997-08-07
MY111402A (en) 2000-04-29
FI950697L (fi) 1995-04-07
ES2111769T3 (es) 1998-03-16
JP3494647B2 (ja) 2004-02-09
HU220103B (hu) 2001-10-28
PL307566A1 (en) 1995-05-29
JPH08500362A (ja) 1996-01-16
EP0671933B1 (fr) 1998-02-04
EP0801951A3 (fr) 1998-05-20
ATE162947T1 (de) 1998-02-15
AU5010893A (en) 1994-03-15
EP0801951A2 (fr) 1997-10-22
RU2120802C1 (ru) 1998-10-27
IL106725A (en) 2000-12-06
KR0170037B1 (ko) 1999-02-01
DK0671933T3 (da) 1998-09-23
RU95108330A (ru) 1996-11-27
CA2142861C (fr) 2000-08-15
CN1090204A (zh) 1994-08-03
FI950697A0 (fi) 1995-02-16
CZ283488B6 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
CA2142861A1 (fr) Usages nouveaux de l'interleukine 4 et/ou de l'interleukine 10, et anticorps diriges contre celles-ci
CA2123321A1 (fr) Chimiotherapie d'association
CA2145093A1 (fr) Inhibiteur therapeutique des cellules musculaires lisses
CA2290520A1 (fr) Inhibition de l'activite de la p38 kinase par des aryl-urees
BG66114B1 (bg) Многофазов състав на дросперидон като контрацептив
CA2229282A1 (fr) Utilisation d'acide hyaluronique en qualite d'agent immunosuppresseur
CA2254079A1 (fr) Derives de l'androstene
IL105170A0 (en) Human tumor necrosis factor muteins,their preparation and pharmaceutical compositions containing them
EP1535929A3 (fr) Facteurs stimulateurs des mégacaryocytes
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
AU4786093A (en) Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression
AU590370B2 (en) Improvements in or relating to pharmaceutical products
DK486189A (da) Psyllium-froeskaller og midler omfattende samme
ATE164731T1 (de) Polyarminearme nähr- und/oder heilmittelzusammensetzung und therapeutische verwendung derselben
CA2100720A1 (fr) Composition medicinale contenant du tcf-ii
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
Goupille et al. Treatment of psoriatic arthropathy
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
CA2099497A1 (fr) Peptides possedant une activite anticoagulante
IL83350A0 (en) Pharmaceutical compositions comprising interleukin and intterferon active substances
IL84722A0 (en) N,n'-disubstituted ureas,their manufacture and pharmaceutical compositions containing them
HUT71838A (en) Use of biologically active ureido derivatives useful in the treatment of lentivirus-induced disease for producing pharmaceutical compositions
Baker FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration
AU1741388A (en) Externally applicable, antiviral pharmaceutical composition accumulating in the skin and process for the preparation of same
AU3980693A (en) New pharmaceutical compositions and new pharmaceutical products allowing the regeneration of leukocytes and their use in the treatment of acquired immuno-deficient syndrom

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed